+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of Cognitive Deficits in Genetic Disorders: A Systematic Review of Clinical Trials of Diet and Drug Treatments

Treatment of Cognitive Deficits in Genetic Disorders: A Systematic Review of Clinical Trials of Diet and Drug Treatments

JAMA Neurology 72(9): 1052-1060

Knowing the underlying etiology of intellectual disability in genetic disorders holds great promise for developing targeted treatments. Although successful preclinical studies and many positive clinical studies have been reported, it is unclear how many purported therapies have become established treatments. The quality of the clinical trials may be an important determinant for achieving clinical impact. To evaluate clinical impact, strengths, and weaknesses of clinical trials of diet or drug treatments to improve cognitive function in patients with a genetic disorder. MEDLINE, EMBASE, PsycINFO, and Cochrane databases were searched from inception date to January 26, 2014, for clinical trials with cognitive outcomes in patients with genetic disorders. Outcome measures of randomized clinical trials (RCTs) were compared between trial registries and reports, and trials were evaluated for the quality of design using the Jadad score and Consolidated Standards of Reporting Trials (CONSORT) criteria. We identified 169 trial reports of 80 treatments for 32 genetic disorders. Seventy-five trials (44.4%) reported potential efficacy, of which only 2 therapies are now established treatments, namely, dietary restriction for phenylketonuria and miglustat for Niemann-Pick disease type C. The median sample size for RCTs was 25 (range, 2-537). Only 30 of 107 RCTs (28.0%) had acceptable Jadad scores exceeding 3. Reporting of key CONSORT items was poor. Reported outcome measures matched preregistered outcome measures in trial registries in only 5 of 107 RCTs (4.7%). The number of trials in the field of cognitive genetic disorders is rapidly growing, but clinical impact has been limited because few drugs have become established treatments and the benefit of most drugs remains unclear. Most trials have small sample sizes and low quality of design. Predefinition of outcome measures, improved trial reporting and design, and international collaboration to increase recruitment are needed to unequivocally determine efficacy of drugs identified in preclinical research.

(PDF emailed within 0-6 h: $19.90)

Accession: 059166464

Download citation: RISBibTeXText

PMID: 26168015

DOI: 10.1001/jamaneurol.2015.0443

Related references

Assessing Randomised Clinical Trials of Cognitive and Exposure Therapies for Gambling Disorders: A Systematic Review. Behaviour Change 30(03): 139-158, 2013

A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy and Behavior 4(2): 124-132, 2003

Efficacy of Ozone Infiltrations in the Treatment of Knee Osteoarthritis Vs Other Interventional Treatments: A Systematic Review of Clinical Trials. Rehabilitacion 53(1): 43-55, 2019

Clinical benefit of intra-articular saline as a comparator in clinical trials of knee osteoarthritis treatments: A systematic review and meta-analysis of randomized trials. Seminars in Arthritis and Rheumatism 46(2): 151-159, 2017

The effectiveness of spinal manipulation for the treatment of headache disorders: A systematic review of randomized clinical trials. Cephalalgia 22(8): 617-623, 2002

The effectiveness of spinal manipulation for the treatment of headache disorders: a systematic review of randomized clinical trials. Cephalalgia 23(6): 479-80; Author Reply 480-1, 2003

Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials. American Journal of Geriatric Psychiatry 23(12): 1234-1249, 2016

Psychological treatments for return to work in individuals on sickness absence due to common mental disorders or musculoskeletal disorders: a systematic review and meta-analysis of randomized-controlled trials. International Archives of Occupational and Environmental Health 2018, 2018

N of 1 trials and the optimal individualisation of drug treatments: a systematic review protocol. Systematic Reviews 6(1): 90, 2018

Drug treatment of scrub typhus: a systematic review and meta-analysis of controlled clinical trials. Transactions of the Royal Society of Tropical Medicine and Hygiene 111(8): 336-344, 2017

Occlusal treatments in temporomandibular disorders: A qualitative systematic review of randomized controlled trials. Pain 83(3): 549-560, 1999

Low-level laser therapy for treatment of neurosensory disorders after orthognathic surgery: A systematic review of randomized clinical trials. Medicina Oral, Patologia Oral Y Cirugia Bucal 22(6): 780-787, 2017

Underrepresentation of patients with pre-existing cognitive impairment in pharmaceutical trials on prophylactic or therapeutic treatments for delirium: a systematic review. Journal of Psychosomatic Research 76(3): 193-199, 2014

Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. European Neuropsychopharmacology 26(12): 1845-1867, 2016

Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials. American Journal of Clinical Oncology 35(6): 593-599, 2013